Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
- Cadranel, Jacques
- Canellas, Anthony
- Matton, Lise
- Darrason, Marie
- Parrot, Antoine
- Naccache, Jean-Marc
- Lavole, Armelle
- Ruppert, Anne-Marie
- Fallet, Vincent
DOIAbstract
International audienceImmune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1/PD-1 ligand inhibitors rather than cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors alone. The frequency of ICI-P is higher when anti-PD-1 and anti-CTLA-4 are administered concomitantly. Despite the low fatality rate (≈13%), ICI-P is the leading cause of ICI-related deaths. This narrative review focuses on the epidemiology, clinical and radiological presentation and prognosis of ICI-P occurring in patients, especially those wi...
Add to ORKG